Neurim wins fight to amend patent for top-selling Circadin amid infringement case

David Shavin 2019-02-19 7:35 pm By Christine Caulfield | Melbourne

Please login to bookmark

Drug maker Neurim Pharmaceuticals has won a bid to amend its Australian patent for top selling sleeping pill Circadin over the protests of two generic pharmaceutical companies, whch argued Neurim had purposely delayed the application to gain an unfair advantage in its infringement suit.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?

For information on rights and reprints, contact subscriptions@lawyerly.com.au